Effects of thalidomide in transfusion-dependent beta-thalassemia patients

Simple item page
dc.contributor.authorHossain, Fariaen_US
dc.contributor.authorSharmeen, Oliaen_US
dc.contributor.authorAlam, Md. Fakhrulen_US
dc.contributor.authorShawon, Md. Hasan Moshiuren_US
dc.contributor.authorRowan, Rowshanen_US
dc.date.accessioned2025-08-13T08:32:57Z
dc.date.available2025-08-13T08:32:57Z
dc.date.issued2025-04
dc.description.abstractBackgrounds: Beta thalassemia constitutes inherited disorders of hemoglobin (Hb) synthesis caused by decreased synthesis of ?-globin chains and relative overproduction of ?-globin chains, causing cell membrane damage, which plays a key role in ineffective erythropoiesis and peripheral hemolysis. Thalidomide, a fetal Hb inducer, shows significant effects in increasing Hb as well as transfusion requirements. This study aimed to evaluate the effects of thalidomide in transfusion-dependent beta-thalassemia patients. Methods: The prospective study was conducted at the Department of Pediatric Hematology and Oncology in collaboration with the Department of Hematology at Sir Salimullah Medical College Mitford Hospital over 1 year, from November 2022 to October 2023. A sample size of 54 with selection criteria included individuals with diagnosed cases of beta thalassemia who were transfusion-dependent. Thalidomide was given at 5 mg/kg/day to all age groups, along with aspirin at 3 mg/kg/day coverage, in addition to conventional therapy. Then, four monthly follow-ups were done for 1 year. Result: Thalidomide leads to an increase in mean Hb levels from 7.06 ± 0.99 g/dL to 9.33 ± 1.16 g/dL (P < 0.001) after 1 year of treatment. The mean number of blood transfusions reduced from 10.98 ± 1.41/year to 10.31 ± 1.36 (P < 0.001) after 1 year of treatment. Conclusion: The study revealed that thalidomide treatment led to a substantial increase in Hb levels as well as a notable decrease in transfusion frequency.en_US
dc.identifier.affiliationsDepartment of Neonatal ICU, Evercare Hospital, Dhaka, Bangladeshen_US
dc.identifier.affiliationsDepartment of Pediatric Hematology and Oncology, Sir Salimullah Medical College Mitford Hospital, Dhaka, Bangladeshen_US
dc.identifier.affiliationsDepartment of Pediatrics, Sir Salimullah Medical College Mitford Hospital, Dhaka, Bangladeshen_US
dc.identifier.affiliationsDepartment of Pediatrics, District Hospital, Pirojpur, Bangladeshen_US
dc.identifier.affiliationsSir Salimullah Medical College Mitford Hospital, Dhaka, Bangladeshen_US
dc.identifier.citationHossain Faria, Sharmeen Olia, Alam Md. Fakhrul, Shawon Md. Hasan Moshiur, Rowan Rowshan. Effects of thalidomide in transfusion-dependent beta-thalassemia patients. Annals of International Medical and Dental Research. 2025 Apr; 11(2): 18-23en_US
dc.identifier.issn2395-2822
dc.identifier.issn2395-2814
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/250001
dc.languageenen_US
dc.publisherScholars Publisheren_US
dc.relation.issuenumber2en_US
dc.relation.volume11en_US
dc.source.urihttps://www.aimdrjournal.com/wp-content/uploads/2025/05/03_AIMDR_4_Karimul_Issue_2_2025.pdfen_US
dc.subjectBeta thalassemiaen_US
dc.subjectblood transfusionen_US
dc.subjecthemoglobinen_US
dc.subjectthalidomide.en_US
dc.titleEffects of thalidomide in transfusion-dependent beta-thalassemia patientsen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
aimdr2025v11n2p18.pdf
Size:
652.85 KB
Format:
Adobe Portable Document Format
Download
Collections
Annals of International Medical and Dental Research